While natural antibodies are monospecific, bispecific antibodies can recognize two different epitopes on the same or different antigens, gaining increasing attention in diagnostic and therapeutic applications. Initially, therapeutic applications were primarily focused on the redirection of effector cells in cancer treatment, including T cells that could not be recruited to tumor cells by normal antibodies. However, over the past decade, researchers have established many other therapeutic strategies based on bispecific antibodies. In addition to retargeting effector molecules, cells and genetic vectors, they have explored dual-targeting and pre-targeting strategies, extending half-life and delivery through biological barriers such as the blood-brain barrier.

（Labrijn AF, et al. Nat Rev Drug Discov. 2019）

One of our antibody engineering services involves the design and expression production of various forms of bispecific antibodies. Starting from hybridoma cell lines or antibody sequences, we can provide customized bispecific antibodies ranging from milligrams to grams.